A real-world study assessing the efficacy and safety of switching from basal bolus insulin therapy to once daily iGlarLixi in people with type 2 diabetes mellitus: soli de-escalation
Authors' conclusion
Switching from BBI to once-daily iGlarLixi improved glycemic control with significant HbA1c reduction and fewer hypoglycemic events.
Study context
- Population
- Adults (≥18 years) with T2D switching from basal-bolus insulin (BBI) to iGlarLixi (01/01/2017–30/09/2022), US Optum Market Clarity® database; mean age 58.9 years, 60.5 % females
- Participants
- 372 adults
- Exposure
- Switch from BBI to once-daily iGlarLixi
- Outcome
- HbA1c change after switching to iGlarLixi
- Follow-up
- 6 months
Methodological detailsreal-world, electronic medical records
- Real-world
- Electronic medical records
Main finding
As reported in the abstract
HbA1c change
HbA1c reduction
0.9 %
p < 0.0001
HbA1c at baseline
9.6 %
HbA1c at 6 months
8.6 %
Observational data: associations, not effects.
Secondary outcomes
HbA1c in subgroup aged ≥65 years · baseline to 6 months
%
- HbA1c decreased from
- 9.3
- HbA1c at 6 months
- 8.4
HbA1c in subgroup with baseline HbA1c ≥7 % · baseline to 6 months
%
- HbA1c decreased from
- 9.8
- HbA1c at 6 months
- 8.8
Proportion achieving HbA1c <7 % (53 mmol/mol) · baseline to 6 months
%
- Doubled from baseline
- 7.0
- At 6 months
- 14.8
Safety
- Hypoglycemia incidence and event rates decreased across all populations
Original publication
A real-world study assessing the efficacy and safety of switching from basal bolus insulin therapy to once daily iGlarLixi in people with type 2 diabetes mellitus: soli de-escalation. Diabetes Res Clin Pract. Published 13 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →